Literature DB >> 8974321

GABAA and NMDA receptor subunit mRNA expression in ethanol dependent rats.

A L Morrow1, L L Devaud, D Bucci, F D Smith.   

Abstract

Recent studies have shown that alterations in gamma-aminobutyric acid (GABAA) and N-methyl-D-aspartate (NMDA) receptor subunit mRNA levels are associated with the effects of chronic ethanol exposure as well as genetic selection for ethanol withdrawal seizure sensitivity. We have previously shown that chronic ethanol exposure in rats results in a decrease in the levels of GABAA receptor alpha 1 and alpha 2 subunit mRNAs in cerebral cortex, an increase in the levels of alpha 6 subunit mRNAs in cerebellum and no alteration in alpha 3, GAD, ribosomal RNA or polyA + RNA levels in these regions. Since chronic ethanol administration increases the expression of [3H]Ro15-4513 binding sites in cortex and cerebellum with no effect on other GABAA receptor recognition sites, we hypothesized that the expression of other subunits would be altered in these regions. In addition, since ethanol appears to interact with zolpidem-sensitive GABAA receptors in rat brain, we investigated the effect of chronic ethanol administration on these recognition sites. Chronic ethanol administration increased [3H]zolpidem binding with no effect on levels of GABAA receptor beta 2 and gamma 2 subunit mRNAs. In addition, we examined the levels of NMDAR1 receptor subunit mRNAs since chronic ethanol administration results in increased levels of [3H]MK-801 recognition sites on NMDA receptors. NMDAR1 receptor subunit mRNAs were not altered following chronic ethanol exposure in rat cortex or hippocampus. These studies underscore the specificity of ethanol interactions with these receptors and the importance of understanding the mechanisms of both GABAA and NMDA receptor regulation in elucidating the etiology of ethanol dependence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8974321

Source DB:  PubMed          Journal:  Alcohol Alcohol Suppl        ISSN: 1358-6173


  9 in total

1.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

2.  Role of altered structure and function of NMDA receptors in development of alcohol dependence.

Authors:  József Nagy; Sándor Kolok; András Boros; Péter Dezso
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 3.  Ethanol modulation of synaptic plasticity.

Authors:  Brian A McCool
Journal:  Neuropharmacology       Date:  2010-12-31       Impact factor: 5.250

Review 4.  Synaptic targets: Chronic alcohol actions.

Authors:  Marisa Roberto; Florence P Varodayan
Journal:  Neuropharmacology       Date:  2017-01-17       Impact factor: 5.250

Review 5.  Synaptic effects induced by alcohol.

Authors:  David M Lovinger; Marisa Roberto
Journal:  Curr Top Behav Neurosci       Date:  2013

6.  Persistence of cerebellar ataxia during chronic ethanol exposure is associated with epigenetic up-regulation of Fmr1 gene expression in rat cerebellum.

Authors:  Russell S Dulman; James Auta; Gabriela M Wandling; Ryan Patwell; Huaibo Zhang; Subhash C Pandey
Journal:  Alcohol Clin Exp Res       Date:  2021-08-28       Impact factor: 3.928

Review 7.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

8.  Ethanol self-administration modulation of NMDA receptor subunit and related synaptic protein mRNA expression in prefrontal cortical fields in cynomolgus monkeys.

Authors:  Glen Acosta; Wendy Hasenkamp; James B Daunais; David P Friedman; Kathleen A Grant; Scott E Hemby
Journal:  Brain Res       Date:  2010-01-04       Impact factor: 3.252

9.  Alcohol related changes in regulation of NMDA receptor functions.

Authors:  József Nagy
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.